Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Devimistat +/- Gemcitabine in Metastatic Pancreatic Cancer
NCT01830322Phase 2Withdrawn
- Sponsor
- Cornerstone Pharmaceuticals
- Start
- Jan 2014
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of devimistat in pancreatic adenocarcinoma (PDAC), sponsored by Cornerstone Pharmaceuticals. Planned start Jan 2014; status: withdrawn.
02
Drugs
devimistat
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01830322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01830322.